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ABSTRACT
Objective Multidisciplinary team (MDT)
meetings are assumed to produce better
decisions and are extensively used to manage
chronic disease in the National Health Service
(NHS). However, evidence for their effectiveness is
mixed. Our objective was to investigate
determinants of MDT effectiveness by examining
factors influencing the implementation of MDT
treatment plans. This is a proxy measure of
effectiveness, because it lies on the pathway to
improvements in health, and reflects team
decision making which has taken account of
clinical and non-clinical information. Additionally,
this measure can be compared across MDTs for
different conditions.
Methods We undertook a prospective mixed-
methods study of 12 MDTs in London and North
Thames. Data were collected by observation of
370 MDT meetings, interviews with 53 MDT
members, and from 2654 patient medical
records. We examined the influence of patient-
related factors (disease, age, sex, deprivation,
whether their preferences and other clinical/
health behaviours were mentioned) and MDT
features (as measured using the ‘Team Climate
Inventory’ and skill mix) on the implementation of
MDT treatment plans.
Results The adjusted odds (or likelihood) of
implementation was reduced by 25% for each
additional professional group represented at the
MDT meeting. Implementation was more likely in
MDTs with clear goals and processes and a good
‘Team Climate’ (adjusted OR 1.96; 95% CI 1.15
to 3.31 for a unit increase in Team Climate
Inventory (TCI) score). Implementation varied by
disease category, with the lowest adjusted odds
of implementation in mental health teams.
Implementation was also lower for patients living
in more deprived areas (adjusted odds of
implementation for patients in the most
compared with least deprived areas was 0.60,
95% CI 0.39 to 0.91).
Conclusions Greater multidisciplinarity is not
necessarily associated with more effective
decision making. Explicit goals and procedures
are also crucial. Decision implementation should
be routinely monitored to ensure the equitable
provision of care.
INTRODUCTION
Multidisciplinary team (MDT) meetings
are central to the management of chronic
disease and they have become widely estab-
lished across the National Health Service
(NHS)1–3 and internationally.4 Their
purpose is to optimise decision making
and improve outcomes.5 Evidence for their
effectiveness, however, is mixed6 7 and the
degree to which MDTs have been absorbed
into clinical practice varies widely across
conditions and settings.8 Research into the
critical factors which impact on MDT
effectiveness has identified clear leader-
ship6 and explicit, shared goals with meas-
urable outcomes.9 A positive team
atmosphere or ‘climate’, defined as shared
perceptions of policies, practices and pro-
cedures,10 has also been found to improve
performance in some studies11 while
others have found no association.12 Other
fundamental determinants of the effective-
ness of MDTs have not been established,
and so, basic questions, such as the
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importance of ‘multidisciplinarity’ in practice, have not
been addressed.
Uncertainty about some of the features associated
with effectiveness has resulted in substantial diversity
in the guidance provided regarding MDT meeting
structure and processes.1 13 14 In the UK, policy for
cancer and community mental health teams (CMHTs)
lists the professional skills required. Cancer teams
follow national standards and are audited to ensure
they fulfil requirements including the routine record-
ing of decisions.8 In other specialties, such as demen-
tia and cardiovascular disease, the format is locally
determined. It is unknown whether such flexibility is
appropriate or undermines the productivity of meet-
ings. Patient-related factors may also impact upon
MDT decisions. There is evidence that the socio-
economically disadvantaged are less likely to receive
healthcare15 despite the focus of NHS policy on
equity.16 If patients’ sociodemographic characteristics
influence MDT effectiveness, then explanations such
as the influence of patient preferences and comorbid-
ities should be sought.17
Given the widespread presence of MDTs, the oppor-
tunity costs for the NHS of unwarranted variations in
team membership and processes and the consequences
for patients of inequitable care, we undertook a prospect-
ive mixed-methods study of a range of chronic disease
MDTs to investigate determinants of effectiveness.
There is debate in the literature concerning the
most appropriate indicator of MDT effectiveness.
Health outcomes may not be the most suitable mea-
sures because they are affected by factors other than
the quality of care, including, for example, the extent
to which patients adhere to treatment.18 19
Additionally, intended health outcomes may not be
evident in the short or medium term, and many out-
comes are disease specific, making it impractical to
compare MDTs for different conditions. Thus, in this
context, the use of a process measure, rather than an
outcome measure, is appropriate.20
However, the identification of an indicator of high-
quality decisions is also difficult. While some decisions
can be compared with national guidelines, these seldom
specify recommended courses of action for every man-
agement decision made for a patient. Additionally,
guidelines rarely consider how decisions should be
modified for patients with comorbidities or other
factors which will influence decision making, such as
their social circumstances or preferences. Finally, guide-
lines are not available for all the conditions considered
in MDT meetings. We identified treatment plan imple-
mentation (as documented in patient notes), as an
appropriate process indicator of effectiveness, because it
lies on the pathway to health improvement and reflects
effective team decision making which has taken account
of relevant clinical and non-clinical information, includ-
ing patient preferences. Another advantage of this
measure is that it can be compared across all MDTs.
Our aim was to identify key characteristics of chronic
disease MDT meetings associated with decision imple-
mentation. To achieve this, we addressed the following
objectives: (1) to examine chronic disease MDT meet-
ings to quantitatively identify factors influencing their
effectiveness in terms of decision implementation and
(2) to explore the reasons for any factors identified
through semistructured interviews and non-participant
observation of meetings.
METHODS
Design
We undertook a prospective cohort study of MDT
meetings in 12 chronic disease adult MDTs across
London and North Thames between December 2010
and December 2012. We aimed to include teams
which varied in terms of healthcare context, profes-
sional mix of team, conditions which affected patients
from different parts of the adult life range, and fatal
versus life-long conditions. We examined one skin
cancer team, one gynaecological cancer team, two
haematological cancer teams, two dementia teams,
two heart failure teams, and four community mental
health teams (including one early intervention service
for psychosis).
Data collection
Data were collected from three sources:
Source A: We undertook non-participant observa-
tion and audiotaped 370 weekly MDT meetings over
18–55 weeks (depending on patient numbers dis-
cussed at each meeting). Each team was observed for
2 weeks before data were collected in order to accus-
tom team members to the observer’s presence. For
each patient discussed, we collected quantitative data
on decisions made and diagnosis. We also recorded
whether health behaviours (smoking, drinking, phys-
ical inactivity), other clinical factors (including
comorbidities, medical and family history) and
patient/carer treatment preferences were mentioned.
For the logistic regression, these categories were col-
lapsed into ‘health behaviours or other clinical factors’
(mentioned or not mentioned) and ‘patient/carer pre-
ferences’ (mentioned or not mentioned). A decision
was defined as a resolution or recommendation about
patient management.
After each meeting, field notes were written on
MDT features (eg, agenda, attendee job titles, pres-
ence of an MDT coordinator), context (eg, reference
to national policy/guidance and local resource issues)
and process (eg, levels of participation, role of the
chair, complexity and uncertainty of problem, and
clarity and documentation of decisions).
Core MDT members (as formally defined in MDT
documents, or by the clinical lead, and excluding
observers and occasional visitors) completed the Team
Climate Inventory (TCI) during the final month of
observation.10 This validated measure21 assessed
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members’ perceptions across the four domains of
‘team vision’, ‘participative safety’ (ie, a facilitative
atmosphere for involvement), ‘task orientation’ (eg,
with respect to individual and team accountability)
and ‘support for innovation’. A low TCI score reflects
perception of poor team climate.
Source B: We conducted semistructured interviews
with 53 MDT members recruited from all the MDTs
observed, purposively sampled to include core profes-
sional groups and frequent and infrequent attendees.
Topics discussed included perceptions of the purpose
and value of MDT meetings as well as the individual’s
role and value within the MDT meeting.
Source C: Quantitative data on decision implemen-
tation, reasons for non-implementation and patients’
sociodemographic (gender, date of birth, and post-
code) and diagnostic details were collected from
medical records. Decision implementation was
assessed 3 months after the MDT meeting unless the
MDT explicitly recorded that implementation should
be later (eg, ‘follow up in six months’).
Summary measures
The data were categorised and scored for analysis
using the following summary measures:
1. Treatment plan (the unit of analysis)
We analysed each patient’s first presentation at an
MDT meeting within the observation period. This
often resulted in more than one decision being made.
These could not be assumed to be independent, and
so, decisions were grouped into a ‘treatment plan’.
Decisions were classified as ‘not implemented’ if there
was no record in the notes indicating decision imple-
mentation. In the majority of cases (88%) implemen-
tation of the treatment plan was fully determined (by
all component decisions being either implemented or
not). In cases where some decisions in the plan were
implemented and others were not, we classified a
treatment plan as implemented if more than 50% of
the component decisions were implemented. This def-
inition was agreed to be reasonable by our study team
but was investigated further in sensitivity analyses.
2. Team Climate Inventory
Responses for each item on the TCI are given on a
5-point Likert scale. The overall team TCI score was
obtained by averaging the scores of team members.
We excluded TCIs with more than 25% of items
missing in one of the TCI dimensions. A unit increase
in TCI score indicates an improvement in team
climate (eg, a change from an average response of
‘agree’ to ‘strongly agree’).
3. Skill mix (Adjusted Teachman’s Index (ATI) and number
of professional groups)
We used the ATI22 together with the number of
professional groups represented (classified as diagnos-
tic medical practitioner, surgeon, physician, MDT
coordinator, nurse, researcher, social worker, allied
health professional and psychologist) to measure
skill mix. See online supplementary appendix Section
1. A higher ATI value reflects a more even spread
across a greater number of groups.23 Use of both mea-
sures allowed consideration of whether the more
complex index added predictive value over a simple
count of professional groups. This was measured at
each individual meeting, and core and non-core staff
were included. Observing students were excluded.
4. Index of Multiple Deprivation
We used the Index of Multiple Deprivation (IMD)
2010 to measure socioeconomic circumstances.24 This
is a widely used area-based measure that combines
seven domains (income, employment, health and dis-
ability, education, skills and training, barriers to
housing and services, and crime and living environ-
ment) into a single deprivation score for each small
geographical area (ie, each ‘lower layer super output
area’ (LSOA), covering about 1500 people) in
England. We grouped IMD scores into quintiles, with
higher quintiles denoting more deprivation. The post-
code address of each patient was linked to the LSOA
and the corresponding deprivation quintile.
Quantitative analysis
The influence of MDT and patient-related factors on
treatment plan implementation was investigated using
random effects logistic regression models, allowing for
clustering by MDT. We fitted unadjusted models for
each factor of interest. We then undertook the following
predefined selection process to obtain a final adjusted
model. Initially, we fitted two separate models. Model 1
included patient characteristics (age, gender and IMD
quintile), and Model 2 considered MDT and decision-
related characteristics (TCI score, disease type, ATI
score, number of professional groups, mention of
patient preferences and other clinical factors (defined as
health behaviours, comorbidities, medical and family
history). Factors identified as having potential import-
ance from these models (p<0.3)25 were then fitted in
the final model (Model 3).
The suitability of models was investigated, including
considering normality of the random effect, goodness
of fit (Hosmer Lemeshow) and evidence of over-
fitting (using bootstrapping). We examined the pattern
and extent of missing data and considered its potential
impact on our results. We also undertook exploratory
investigations to understand further the associations
observed in our model and whether these differed by
disease type. We extended Model 3 to examine inter-
action terms between the number of professional
groups and disease type and between IMD and
guideline-driven cancer compared with non-cancer
MDTs.
Planned sample size
The sample size calculation was based on decision
implementation, assuming one decision for each
patient.
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As patients could have more than one decision
when presented at an MDT, and these could not be
assumed to be independent, we grouped these deci-
sions to consider implementation of their overall
‘treatment plan’ for analysis. Where patients were dis-
cussed at more than one MDT, we analysed the treat-
ment plan from their first presentation during the
observation period.
We calculated the sample size using the conservative
assumption (based on published research and clinical
experience) that 18% of decisions would not be
implemented.26 Using Peduzzi’s rule of 10, we
required 80 non-implemented decisions to estimate
eight coefficients in our regression model; this would
require approximately 440 patients.27 To allow for
clustering by MDT, the sample size was inflated using
estimates of the intracluster correlation coefficient
(ICC) and the average cluster size. Directly relevant
estimates for the ICC were not available, however,
published models associating the ICC and outcome
prevalence for a range of outcomes in community and
health services settings suggested an ICC between
0.01 and 0.05.28 Thus, we assumed an ICC of 0.025,
and that across MDTs the average number of patients
with relevant decisions during the study would be
approximately 230. Based on this information, we
aimed to include 3000 patients with a decision from
the 12 MDTs.
Qualitative analysis
Qualitative observational and interview data were
used to explore possible reasons for variations in
implementation across teams and disease types. Our
approach used deductive themes based on the main
quantitative findings and inductive coding to expand
on the deductive codes and to explore relevant emer-
ging issues.
For the interview analysis, all transcripts were
coded, checked and analysed in a constant compara-
tive manner by three field researchers using NVivo
software (V9). For the observational analysis, we
coded field notes for the first 16 meetings observed
for each of the 12 MDTs (excluding 2 weeks of pilot
observation with each team) and selectively tran-
scribed portions of these. Having listened to all 370
meetings at least twice, the researchers were confident
that the 192 meetings coded in this way were
representative.
Having coded approximately 1/3 of the data, we
found that our coding framework became stable.
During analysis of the remaining data we did not need
to add further codes to describe the data in relation to
our aims and develop a meaningful and useful inter-
pretation, suggesting a sufficiently high level of
saturation.29
Analytic meetings involving the wider research team
were held to review, refine and cluster the codes into
organising themes, resolve disagreements and ensure
consistency of interpretation. Conducting qualitative
analysis as a team safeguarded against bias, and facili-
tated a richer conceptual analysis and interpretation.30
Qualitative data were then triangulated to examine the
consistency and internal validity of findings, identify-
ing patterns of convergence in order to develop a
coherent framework for understanding the results
overall. Further details are provided in the online sup-
plementary appendix Section 2.
RESULTS
We observed 370 MDT meetings during which 3184
patients were discussed. There was considerable vari-
ability among the 12 teams in the number of patients
discussed at each meeting. The average for each team
ranged from 4 to 49 patients. The meeting size across
the 12 MDTs ranged between 5 and 28 members, with
1–7 professional groups represented (a median of 4).
Quantitative results (objective I)
Overall, 2654 patients had a treatment plan with an
average of 1.6 decisions per plan. Two thousand five
hundred and twelve (95%) patients had adequate
implementation data recorded, of whom 1967 (78%)
had implemented plans. Implementation was highest
in the gynaecological cancer team and lowest in the
CMHTs (table 1). There was a trend for non-
implementation with increasing patient deprivation.
Adjusted associations (table 2) showed no evidence
of a relationship between treatment plan implementa-
tion and patient age or gender, or with discussion of
patient preferences or health behaviours/other clinical
factors. ATI and number of professional groups were
highly correlated (correlation coefficient 0.8) and did
not appear to have an association when fitted together
(Model 2). When included individually in the model,
however, each showed a relationship such that
increases in team diversity or number of professional
groups were associated with a reduced odds of treat-
ment plan implementation (table 2 footnote).
Factors with an association (p<0.3)25 in Models 1
and 2 were fitted together in the final model
(Model 3). The adjusted odds of implementation
almost doubled (OR 1.96 (95% CI 1.15 to 3.31) for a
unit increase in TCI score (indicating improved team
climate). By contrast, the adjusted odds of implemen-
tation was reduced by 25% for each additional profes-
sional group represented and was lower for patients
living in more deprived IMD quintiles. Adjusted odds
of implementation also varied by disease type.
We had sufficient data on 2512 (92%) patients to
include them in the final model. Data were missing
for age (2%), IMD quintile (6%) and treatment plan
implementation (5%), mainly because of missing
patient notes. The only characteristic associated with
missingness was MDT disease type. Given the small
proportion of missing values, we did not consider it
necessary to account for this in our analysis.
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Sensitivity analyses for Model 3 included: adjusting
for the number of decisions making up the first treat-
ment plan (which varied between 1 and 11 decisions);
examining the impact of using the first recorded treat-
ment plan in analysis by refitting the model based on
a randomly chosen treatment plan for each patient;
collapsing the 5 IMD quintiles to two groups
(IMD1-3 and IMD 4–5) to produce an 8 coefficient
model; refitting the model with implemented treat-
ment plans redefined as those with greater than 80%
of component decisions implemented (a change which
had little impact on the overall implementation rate
reducing it from 78% to 74%); and refitting the
model excluding the CMHTs (which made up a large
proportion of the teams in the study). None of these
sensitivity analyses substantially changed our
conclusions.
We further explored the observed trend between
implementation and number of professional groups to
consider whether this might be dependent on disease
type. Tabulations showed that for dementia teams and
CMHTs this trend was apparent. For the other disease
types, however, such a trend was not obvious. An
interaction term added to Model 3 indicated some
evidence of a differential effect by type of disease
(p=0.06), however, we note that this exploratory
result should be interpreted cautiously, as for some
diseases, there was limited variability in the number of
professional categories represented. We also consid-
ered whether the relationship between IMD and
implementation differed for cancer and non-cancer
specialties. In all cases, the observed general trend was
for less implementation in more deprived groups. An
interaction term included in Model 3 was not signifi-
cant (p=0.13).
The reasons for non-implementation of treatment
plans are summarised in table 3. Patient-led reasons
were recorded most frequently in CMHTs (eg, due to
patient non-attendance), while patient death was
reported most frequently for heart failure MDTs (see
online supplementary appendix. Section 3 summarises
reasons for non-implementation by disease type). We
also collapsed the 5 IMD quintiles to two groups
(IMD1-3 and IMD 4–5), and found that reasons for
non-implementation were similar, although patient
death was a more frequent reason for non-
implementation in the least deprived group (data not
shown). The ‘other’ reasons were diverse, and
included cases where the decision was implemented
outside the 3-month follow-up period, or when new
information or test results emerged after the MDT
meeting. This category also included cases where it
was subsequently decided that a referral had been
inappropriate or that a patient should have been
referred to a team in a different catchment area.
Qualitative results (objective II)
Features of teams with higher rates of treatment plan implementation
High implementing MDTs, regardless of disease type,
had clear goals and more frequently referred to diag-
nostic or treatment protocols and national guidelines.
All four cancer teams adhered closely to national
guidelines, and so, had the dedicated administrative
support members considered to be essential for
meeting preparation and facilitation. High implement-
ing teams also tended to have permanent chairs who
Table 1 Frequency (%) of treatment plan implementation by
patient, MDT and discussion characteristics
Treatment plan implemented
(number (%))
Age (years) (n=2504)
20–39 355 (73)
40–59 488 (79)
60–79 739 (81)
80+ 381 (80)
Gender
Males 945 (78)
Females 1022 (79)
Index of multiple deprivation (IMD) quintile (n=2431)
Least deprived 197 (85)
2 331 (82)
3 395 (82)
4 541 (76)
Most deprived 442 (73)
Team Climate Inventory (TCI)*‡
<4 (median score) 853 (78)
>=4 1114 (79)
Type of disease team*
Haematological cancer 502 (81)
Community mental health 403 (70)
Dementia 362 (81)
Heart failure 243 (80)
Skin cancer 229 (78)
Gynaecological cancer 228 (84)
Adjusted Teachman’s†
<1.2 349 (82)
1.2 to 1.4 538 (76)
1.4 to 1.6 591 (78)
>1.6 489 (78)
Number of professional groups†
1–3 312 (81)
4–5 1199 (77)
6–7 456 (79)
Patient preferences considered
Yes 361 (75)
No 1606 (79)
Health behaviours/other clinical factors mentioned
Yes 1069 (79)
No 898 (77)
*Measures recorded for individual teams.
†Measures recorded for individual meetings.
‡Average team response rate=76%.
MDT, Multidisciplinary team.
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Table 2 Associations between treatment plan implementation and patient and team characteristics; unadjusted and adjusted results from logistic regression models allowing for clustering by
team*
Unadjusted (n=2512)† Adjusted Model 1 (n=2431) Adjusted Model 2 (n=2512) Adjusted Model 3 (n=2431)
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Age (at first decision) (1 year increase) 1.00 (0.99 to 1.01) 0.60 1.00 (0.99 to 1.01) 0.84
Gender
Male 1 1
Female 0.99 (0.80 to 1.21) 0.89 1.01 (0.82 to 1.24) 0.96
IMD quintile
Least deprived 1 1 1
2 0.83 (0.53 to 1.30) 0.83 (0.53 to 1.30) 0.80 (0.52 to 1.25)
3 0.91 (0.58 to 1.40) 0.91 (0.58 to 1.40) 0.87 (0.56 to 1.34)
4 0.64 (0.43 to 0.98) 0.65 (0.43 to 0.99) 0.64 (0.42 to 0.97)
Most deprived 0.60 (0.39 to 0.93) 0.04 0.60 (0.39 to 0.93) 0.04 0.60 (0.39 to 0.91) 0.05
TCI (1 unit increase) 1.68 (0.70 to 4.03) 0.25 2.28 (1.30 to 4.00) 0.004 1.96 (1.15 to 3.31) 0.01
Type of disease team
Haematological cancer 1 1 1
Community mental health 0.56 (0.35 to 0.90) 0.60 (0.37 to 0.99) 0.57 (0.39 to 0.82)
Dementia 1.21 (0.67 to 2.20) 1.11 (0.74 to 1.67) 1.05 (0.76 to 1.45)
Heart failure 0.93 (0.52 to 1.54) 0.03 0.78 (0.49 to 1.21) <0.001 0.75 (0.50 to 1.14) <0.001
Skin cancer 0.81 (0.42 to 1.56) 0.97 (0.67 to 1.39) 0.97 (0.67 to 1.39)
Gynaecological cancer 1.22 (0.62 to 2.38) 2.76 (1.58 to 4.83) 2.48 (1.48 to 4.15)
Adjusted Teachman’s (ATI) (1 unit increase) 0.64 (0.35 to 1.17) 0.15 0.65 (0.24 to 1.76)‡ 0.40
Number of professional groups 0.90 (0.77 to 1.06) 0.21 0.84 (0.65 to 1.10)‡ 0.21 0.75 (0.66 to 0.87) <0.001
Patient preferences considered
No 1 0.24 1 0.34
Yes 0.86 (0.67 to 1.11) 0.89 (0.69 to 1.14)
Health behaviours/other clinical factors mentioned
No 1 0.80 1 0.55
Yes 1.03 (0.83 to 1.27) 1.07 (0.86 to 1.32)
*Intra cluster correlation coefficient for team clustering=0.05 (bootstrap 95% CI 0.01 to 0.08).
†For age n=2504 and for IMD quintile n=2431.
‡ATI and number of professional groups are highly correlated (correlation coefficient 0.8). When included individually in model 2, each showed a significant relationship: OR for ATI=0.38 (95% CI 0.23 to 0.63) p<0.001,
OR for number of professional groups=0.76 (95% CI 0.67 to 0.87) p<0.001.
IMD, Index of Multiple Deprivation; TCI, Team Climate Inventory.
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maintained a focus on decisions, which were clearly
recorded. They also assembled patient lists before
meetings. This stimulated case presenters to consider
the management options they wished to discuss
before rather than during the meeting and led to
more explicit decisions. The other MDTs included
none or some of these features, and this varied by
team rather than by disease type.
Features of teams with lower rates of treatment plan implementation
Those dementia and CMHT meetings with larger
numbers of professional groups and lower implemen-
tation tended to discuss a more diverse range of issues
(from medication to social issues, housing and bene-
fits), and also used meetings to provide updates on
ongoing cases and peer support. There was some evi-
dence that these teams lacked clarity of purpose:
I am never quite sure what the purpose of the meet-
ings are (psychiatric nurse, interview),
and were less focused on specific questions:
Thanks for sharing that story. Why did we hear it?
(psychiatrist, observation).
Decision documentation was inconsistent, and
CMHT members frequently discussed difficulties in
engaging patients with the service which also contrib-
uted to the low implementation in these teams.
Chairing arrangements
Chairing varied considerably between teams. Most
meetings were formally chaired: in cancer teams, one
dementia team and two CMHTs, this was a designated
person who chaired the meeting each week (either a
consultant or the team manager). In two mental
health teams, the chairing role rotated between team
members on a weekly basis. The remaining three
teams did not have a predefined chairing system, and
different senior members took the lead on different
occasions, sometimes changing during a meeting.
Multidisciplinary working
Team members reported that they valued hearing a
range of disciplinary perspectives, however, not all
disciplines were perceived to have an equal ‘voice’.
Cancer and heart failure teams were characterised by
a strong medical dominance in terms of attendance
and participation. While these teams typically made
and implemented high numbers of treatment plans,
those plans were less likely to have incorporated the
full range of disciplinary perspectives:
It’s rarely a multidisciplinary meeting…it often con-
sists of a surgeon talking to the radiologist (gynaeco-
logical cancer oncologist, interview).
CMHT and dementia teams were characterised by
more even levels of participation across the disci-
plines, however, interviews revealed that differences
in the ways that professional groups approached pro-
blems could lead to difficulties:
They’re in two camps… social workers very much do
try to defend, you know, a person’s right to be mad. I
mean the nurse view is ‘you’re not well so we need to
get you on the path and let’s make the decisions you
would make [if you were well]’ (psychiatric nurse,
interview).
Patient factors
We explored the roles that patient preference, health
behaviours and other clinical factors may have in
explaining the socioeconomic variations in implemen-
tation that we found. However, most members consid-
ered that the extent to which patient behaviours and
other factors were discussed was appropriate,
although there was marked team variation in discus-
sion of these factors. With regard to patient prefer-
ences, some argued that these were central to MDT
decisions while others tended to elicit patient prefer-
ences after the MDT, when treatment options could
be shared with them.
Further quotes illustrating these findings are pro-
vided in Section 4 of the online supplementary
appendix.
DISCUSSION
In this large study, the first to include MDTs for dif-
ferent conditions, we demonstrate the implications of
MDT diversity for the NHS and patient care. We have
shown that a good team climate and less diverse mem-
bership in the MDTwere the most important predic-
tors of treatment plan implementation across teams.
There was variation within and between disease types
with gynaecological cancer having the highest rates of
treatment plan implementation, and CMHTs the
lowest. There was less implementation for patients
living in more deprived areas. Lack of implementation
Table 3 Reasons for non-implementation for decisions in the
first treatment plan
Reason for non-implementation of
treatment decision*
Number (%)
n=355
Patient/carer/family choice 54 (15)
Change in circumstances† 40 (11)
Patient did not attend 36 (10)
Decision was conditional and condition was not met 21 (6)
Patient died 19 (5)
Comorbidity arising post-MDT meeting, or deteriorated
post-MDT meeting
6 (2)
Comorbidity not discussed 7 (2)
Other‡ 98 (28)
Non-implementation recorded but reason not given 74 (21)
*Where non-implementation was recorded in the notes.
†For example, patient left the care of team.
‡New information or test results emerged after the MDT meeting;
incorrect or missing information at the MDT meeting; decision was
implemented outside of the 3-month follow-up period.
MDT, Multidisciplinary team.
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was commonly due to patient or family choice, and to
difficulties in engaging patients with the service. The
better implementing teams tended to have dedicated
administrative support and clear goals and processes.
Contrary to previous reports and expectations,
greater multidisciplinarity is not necessarily associated
with more effective decision making. Previous
research suggests that each team member brings rele-
vant information for the development of a cohesive
care plan.31 However, diversity may raise communica-
tion barriers due to differences in knowledge, skills
and ability,9 misunderstandings of each other’s
roles,32 and identifying with subgroups rather than
with the team as a whole.33 Our research suggests that
the presence of many professional groups needs to be
mediated by a clear purpose and agreed processes.
This is supported by evidence which points to the
benefits of shared objectives to guide and structure
communication, focused leadership, and team
reflexivity.9 34
Second, our results concur with others which
demonstrated that a good team climate does translate
to better decisions.11 It had been suggested that trans-
formational leadership affects team performance
(better decisions) by creating a positive climate.35 It is
also possible that the mixed results in the literature
are explained by the different outcome measures used
to define effectiveness.12
Finally, patients from more deprived areas are less
likely to have their treatment plans implemented, and
this occurred despite the routine reference to treat-
ment guidelines by cancer teams. Consideration of
patient preference, comorbidities or other
health-related factors do not seem to explain this.
Previous research reporting socioeconomic inequal-
ities in use of adjuvant therapy for cancer suggests
that non-implementation equates to non-uptake of
care for cancer patients.36 This is likely to partly
explain the continuing socioeconomic variations in
cancer survival.37 There is little research on treatment
inequalities for people with dementia, although a
small study indicates that these may occur.38 Recent
models demonstrated equitable provision of cardiovas-
cular care which translated to similar proportions of
deaths averted across deprivation quintiles.39
However, non-implementation may result in care
delays which might impact upon morbidity rather
than mortality—something that was not addressed in
these cardiovascular models.
Methodological issues
We recognise that the use of decision implementation
as an indicator of effectiveness does not address the
issue of whether or not the ‘right’ decisions have been
made. It is possible that poor decisions are implemen-
ted. In order to examine whether implemented deci-
sions are ‘good decisions’ that do indeed lead to
patient benefit, it would be necessary to analyse
carefully identified disease-specific health outcomes
which can be plausibly and directly related to the
MDT decision. Alternatively, a subset of decisions
about which there are specific best practice guidelines
could be assessed according to whether they conform
to this guidance. However, many MDT decisions
cannot be derived directly from treatment guidelines,
and the detail provided in such guidelines varies by
specialty.
Additionally, the factors we considered in our ana-
lyses were identified as potentially important based on
previous research. We appreciate that there may be
other, unmeasured factors that could also have influ-
enced implementation. Furthermore, decision making
is only one of a range of functions for some MDT
meetings, and in particular for the CMHTs we
studied. Our outcome measure was not designed to
assess how well these additional functions were
performed.
When deciding which and how many chronic dis-
eases to include, in addition to the criteria described
above, we were also bound by pragmatic imperatives
to ensure feasibility of data collection. We recognise
that this has implications for the generalisability of
our results, in terms of applicability to other chronic
conditions and with respect to the similarity of the
MDTs we examined in comparison to other MDTs
for the conditions under study. For this reason, we
included more than one MDT wherever possible.
Online supplementary appendix Sections 5 and 6
report team and meeting characteristics to assist
readers in assessing the extent to which our results are
likely to be applicable to other teams.
We combined decisions where implementation was
‘not documented’ with those decisions which were
‘not implemented’. This was because, on the basis of
our clinical experience, non-implementation is com-
monly not explicitly recorded in patients’ records.
Our conclusions are, therefore, limited by the accur-
acy of record keeping.
There is no consensus on the best measure of skill
mix or team diversity.23 We therefore categorised
professionals into coherent groups on the basis of our
clinical expertise. We used a well-established area
measure of socioeconomic characteristics, commonly
used where individual-level indicators are not available.
However, this method rests on the assumption that
individuals conform to the socioeconomic profile of
their residential area. We recognise that misclassifica-
tions can cause underestimates or overestimates of the
relation between socioeconomic circumstances and
implementation.
We did not achieve the target sample size of 3000
individual patients with treatment plans. This is
because fewer patients than anticipated had treatment
plans agreed at each meeting. However, even with our
smaller sample, investigation into model overfitting
did not raise concerns.
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We did not collect cost or waiting time data, and so,
cannot comment on the implications of MDT diver-
sity with respect to MDT cost effectiveness or conse-
quences for patients.
It is possible that team members behaved differently
when under observation, but this was mitigated by the
2 weeks of observation before data were collected.
Additionally, MDT members were aware that decision
making was being studied, but not that implementa-
tion was being examined.
Conclusion
MDTs are widespread across the NHS, but they are
resource intensive, and so their value to the NHS and
patients should be maximised. A team atmosphere
that facilitates involvement, task orientation and
support for improvement is key to ensuring team deci-
sions are implemented. The benefits of multidiscipli-
narity per se should not be assumed. However, clear
goals and procedures are crucial, and we also recom-
mend routinely monitoring decision implementation
to ensure the equitable provision of care.
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